Passive vs. active targeting: an update of the EPR role in drug delivery to tumors
págs. 3-45
The “EX” and the “SOMA”: how they communicate
Pinar Kanlikilicer, Mohammed Helmy Rashed, Bulent Ozpolat, Cristian Rodríguez-Aguayo, K. K. Sood, George A. Calin, Gabriel López-Berestein
págs. 47-63
págs. 67-94
págs. 95-122
Photodynamic therapy for cancer:: principles, clinical applications, and nanotechnological approaches
Claudia Conte, Francesca Ungaro, Antonio Mazzaglia, Fabiana Quaglia
págs. 123-160
Cancer vaccines: fundamentals and strategies
págs. 163-185
Cancer immune modulation and immunosuppressive cells: current and future therapeutic approaches
págs. 187-214
Nanotechnology approaches for cancer immunotherapy and immunomodulation
María de la Fuente Freire, Robert Langer, María José Alonso Fernández
págs. 215-224
RNAi-based nano-oncologicals: delivery and clinical applications
págs. 245-268
págs. 269-291
Multifunctional gold nanocarriers for cancer theranostics: from bench to bedside and back again?
Joao Conde, Furong Tian, Pedro V. Baptista, Jesús M. de Fuente
págs. 295-328
págs. 329-350
págs. 351-388
Nanotoxicology: towards safety by design
Fernando Torres Andón, Bengt Fadeel
págs. 391-424
Regulatory aspects of oncologicals: nanosystems main challenges
Rogério S. Gaspar, Helena F. Florindo, Liana C. Silva, Mafalda A. Videira, M. Luísa Corvo, Bárbara F. Martins, Beatriz Silva-Lima
págs. 425-452
BO-110, a dsRNA-based anticancer agent: case study : gene therapy using polymer carriers
Mercedes Pozuelo-Rubio, Damiá Tormo Carulla, Andrés Pablo Gagete Mateos, María Soengas
págs. 453-470
© 2001-2024 Fundación Dialnet · Todos los derechos reservados